ADME Toxicology Testing Market

ADME Toxicology Testing Market Size (2021 to 2026)

As per our report, the global ADME toxicology testing market size is estimated to grow a CAGR of 12.2% from 2021 to 2026.

ADME toxicology testing performance is directly dependent on the toxicity of the drug and having lower side effects with high positive results in reducing the health disorder. With increasing concern over animal rights, in vitro technology is highly recommended in almost every laboratory to have better benefits. The prediction technology is all good to have the highest growth rate in the foreseen years with varied advantages. North America is positioned first in holding the most significant shares of the global ADME toxicology testing market.

MARKET DRIVERS:

The rapid increase in several diseases and the demand for the discovery of new medicines to lower the risk of death and other effects are primarily accelerating the growth of the global ADME toxicology testing market.

The support from the government in investments to launch various new products is impacting the positive development of the global ADME toxicology testing market. The adoption of new techniques in finding a way to launch different products in significantly less time and lower side effects provides growth opportunities for the market. The reduced cost of affordable medicines by ordinary people due to ADME toxicology testing is lavishing the market's chance to grow extensively. 

The global ADME toxicology testing market receives support from technological advancements such as in silico techniques that use computer-based testing methods for faster performance to grow further. Modern cell-based assays are gaining a lot of traction worldwide, and this demand will continue to grow in the future. During the forecast period, ongoing R&D in ADME toxicology testing is expected to open up new opportunities. North America currently has the largest share of the global ADME toxicology testing market, and it is projected to continue to do so in the future.

MARKET RESTRAINTS:

However, fluctuations in the availability of raw materials are hampering the growth of the market. The increasing prices of pharmaceutical products and violations in following rules and regulations by agencies are challenging factors in the global ADME toxicology testing market.

Several of these techniques require advanced knowledge and software that can manage and store large volumes of data quickly, lack of in-vitro models to detect autoimmunity and immune stimulation might restrict market expansion to some extent. Furthermore, the market's growth is likely to be hampered by a shortage of efficient software to manage automated robotic arms and liquid handling systems. In the United States, the COVID-19 outbreak has been growing at an exponential rate. This has resulted in a decrease in the number of daily patient visits to hospitals and clinics and a decrease in the number of profiling studies performed under normal conditions. To some extent, this is expected to stifle the global ADME toxicology testing market growth.

High research costs and strict government rules and regulations associated with ADME toxicology testing, on the other hand, are major challenges to the market's expansion. A lack of understanding of the underlying scientific principles and the proper technique selection results in various direct and indirect costs. As a result, highly skilled personnel are required to create, validate, service, and troubleshoot. These are the challenges faced by the ADME toxicology Testing Market.

COVID-19 impact on the global ADME toxicology testing market:

Health supplies and equipment are at risk of running out due to the rapid spread of COVID-19. COVID-19 hasn't had a significant effect on raw material supplies for toxicology technologies, aside from transportation delays caused by travel restrictions and some driver shortage problems. The demand for toxicology technologies, especially diagnostic assays and PCR, has increased, with the demand for faster testing and research in the field. Various diagnostic kits, such as PCR testing panels and medications, have been licensed by the FDA for emergency use in COVID -19 testing and diagnostics. The ADME Toxicology Screening System is an interactive workstation that defines the properties of drug molecules in terms of absorption, distribution, metabolism, and excretion. Furthermore, due to the widespread outbreak of coronavirus disease (COVID-19) and the lack of an effective vaccine or treatment, ADME toxicology testing is being used to assess existing drugs' efficacy as an alternative treatment is increasing market growth.

REPORT COVERAGE:

This research report on the global ADME toxicology testing market has been segmented and sub-segmented based on the method, technology, application, end-user, and region.

ADME Toxicology Testing Market – By Method:

• Cellular Assay
• Biochemical Assay
• In Silica
• Ex-vivo

The cellular assay segment is expected to occupy a substantial share in the global ADME toxicology testing market based on the product. Factors such as accurate, highly detailed methods are the reason for segment growth. These assays don’t eliminate clinical experiments, but they make human research successful with less risky action to achieve better results.

ADME Toxicology Testing Market – By Technology:

• Cell Culture
• High Throughput
• Molecular Imaging
• OMICS Technology

Based on technology, Cell Culture technology to have a dominant share in the global ADME toxicology testing market. From 2D cell culture to 3D cell culture, the transformation is completed where 3D shows the visual result and the skill to test in lower volumes.

ADME Toxicology Testing Market – By Application:

• Systemic Toxicity
• Renal Toxicity
• Hepatotoxicity
• Neurotoxicity
• Others

Based on the application, Systemic toxicity held a prominent market share. It continued its power and influence throughout the period due to the upward or forward movement in Cardiology's toxicity studies. Systemic toxicity continues to have its power and influence throughout the period. It is the most chosen drug distribution method, which is also one of the crucial causes of toxic reactions. Renal and Hepatotoxicity are the major applications to witness rapid growth in the future.

ADME Toxicology Testing Market – By End-Users:

• Hospitals and clinics
• Diagnostic centers
• Pathological Labs
• Others

ADME Toxicology Testing Market – By Region:

• North America
  • The U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of EU
• Asia-Pacific
  • India
  • China
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Rest of Latin America
• Middle East
• Africa

Geographically, the global ADME toxicology testing market is looking forward to a steady pace throughout the forecast timespan. North American ADME Toxicology Testing Market is positioned first in holding the highest shares of the global market. The quick adoption of the latest technologies and maintaining strict management rules by the government propel the market demand in this region.

The Asia Pacific and Europe regions are to have dominant shares shortly. Changes in the policies favoring pharmaceutical companies and the growing number of research institutes help the market grow.

KEY MARKET PLAYERS:

Some of the noteworthy companies dominating the global ADME toxicology testing market profiled in this report are Promega Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Cellartis AB, Cyprotex PLC., Life Technologies Corporation, Optivia Biotechnology, Inc., Accelrys, Inc., Molecular Discovery Ltd., Cyprotex PLC and MultiCASE, Inc.

RECENT MARKET HAPPENINGS:

• In February 2020, QLinea AB announced that the company had made a partnership with Thermo Fischer scientific to commercialize ASTar. 
• In February 2020, TFS introduced the IonTorrent CarrierSeq ECS Kit for expanding their careers.  
• In February 2020, Thermo Fisher collaborated with the NanoPin diagnostic platform for rapid and quantified results from patient blood-based infectious disease detection technology through the development of liquid chromatography-mass spectrometry (LC-MS) based workflows. 
• In January 2020, TFS launched the next-generation compressor-free plate sealer at SLAS 2020.  
• In November 2019, TFS launched the latest Forensic Qualified, an affordable and easy-to-use capillary electrophoresis platform. 
• In October 2019, Arctoris announced a partnership with Molecule to tackle the ongoing crisis. Actors made the researchers and biotechnological entrepreneurs design and executed advanced cell-based and molecular biology through its automated drug discovery platform.